Department of Orthopaedics, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Department of Haemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Jun;164(2):168-176. doi: 10.5507/bp.2019.034. Epub 2019 Sep 16.
We assessed various ways of tranexamic acid (TXA) administration on the fibrinolytic system. Blood loss, transfusions, drainage and haematoma were secondary outcomes.
In this prospective study, we examined 100 patients undergoing primary total knee arthroplasty (TKA) between June and November 2018. Patients were randomly assigned to 4 groups according to the following TXA regimens: 1) loading dose 15 mg TXA/kg single intravenous administration applied at initiation of anesthesia (IV1); 2) loading dose 15 mg TXA/kg + additional dose 15 mg TXA/kg 6 h after the first application of TXA (IV2); 3) IV1 regime in combination with a local wash of 2 g of TXA in 50 mL of saline (COMB); 4) topical administration of 2 g of TXA in 50 mL of saline (TOP).
Systemic fibrinolysis interference was insignificant in all of the regimens; we did not detect significant differences between IV1, IV2 and COMB in the monitored parameters within the elapsed time after the TKA; IV regimes had the lowest total drainage blood loss; the lowest blood loss was associated with the IV1 and IV2 regimens (IV1, IV2 < COMB < TOP); the lowest incidence of haematomas was in patients treated with TXA topically (i.e., in COMB + TOP).
The largest antifibrinolytic effect was associated with intravenous administration of TXA. In terms of blood loss, intravenously administered TXA can interfere with the processes associated with the formation of the fibrin plug more efficiently than the simple washing of wound surfaces with TXA.
我们评估了氨甲环酸(TXA)不同给药方式对纤溶系统的影响。失血、输血、引流和血肿为次要结果。
在这项前瞻性研究中,我们检查了 2018 年 6 月至 11 月期间接受初次全膝关节置换术(TKA)的 100 例患者。患者根据以下 TXA 方案随机分为 4 组:1)麻醉开始时单次静脉注射 15mg/kg 负荷剂量 TXA(IV1);2)首次应用 TXA 后 6 小时给予 15mg/kg 负荷剂量 TXA+额外 15mg/kg 剂量(IV2);3)IV1 方案联合局部冲洗 2g TXA 于 50ml 生理盐水(COMB);4)局部应用 2g TXA 于 50ml 生理盐水(TOP)。
所有方案均未观察到系统性纤溶干扰;在 TKA 后监测的参数在经过的时间内,IV1、IV2 和 COMB 之间没有观察到显著差异;IV 方案的总引流失血量最低;与 IV1 和 IV2 方案相比,IV 方案的失血量最低(IV1、IV2<COMB<TOP);局部应用 TXA 的患者(即 COMB+TOP)血肿发生率最低。
静脉应用 TXA 的抗纤溶效果最大。就失血而言,静脉内给予 TXA 比单纯用 TXA 冲洗创面更能有效地干扰与纤维蛋白塞形成相关的过程。